A Phase 1 interventional study of Roflumilast and Placebo in Schizophrenia, sponsored by Takeda. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-10-03.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.
Among the 11 studies in Schizophrenia by Takeda, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 1, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 20 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Schizophrenia by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable schizophrenia.
The drug being tested in this study is called roflumilast. Roflumilast is being tested as an add-on treatment to second generation antipsychotics (SGA) to treat cognitive impairment in people with stable schizophrenia. This study will look at improvement in cognitive impairment associated with schizophrenia in people who take roflumilast as an add-on to SGA.
The study will enroll approximately 22 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need) All participants will receive the following treatments at different periods throughout the study:
All participants will be asked to take one tablet at the same time each day throughout the study.
This single-centre trial will be conducted in the United Kingdom. The overall time to participate in this study is up to 64 days. Participants will make 2 screening visits to the clinic and then must be brought to the clinic every day for dosing during each of 3 Treatment Periods. Each Treatment Period will be 8 days in duration. All participants will also make 1 final visit 14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
Drug: Roflumilast · Drug: Placebo · Drug: Second generation antipsychotic
Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
Drug: Roflumilast · Drug: Placebo · Drug: Second generation antipsychotic
Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
Drug: Roflumilast · Drug: Placebo · Drug: Second generation antipsychotic
Roflumilast tablets
Also known as: DALIRESP®, DAXAS®
Roflumilast placebo-matching tablets
Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
Change From Baseline in Spatial Span Test Score
The Spatial Span test assesses the participant's working memory. During this task, participants are presented with a board containing blue blocks randomly arranged. The rater first taps out a pattern of blocks, beginning with two blocks and increasing with participant proficiency, and the participant is tasked with tapping the same pattern. After discontinuation of this part of the subtest, the participant is then tasked with tapping out the reverse pattern after the rater's demonstration. These patterns also begin with two blocks and increase with participant proficiency. The total score for this subtest ranges from 0 (worst) to 32 (best). A positive change from Baseline indicates improvement. Analysis of Variance (ANOVA) with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Hopkins Verbal Learning Test (HVLT) Score
The HVLT assesses the participant's verbal learning. The test consists of a list of 12 words from three taxonomic categories which are presented orally, and the participant is asked to recall as many as possible after each of three learning trials. The key outcome variable for this task is the total correct responses in the three learning trials. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Dorsolateral Prefrontal Cortex Activation During the Rewarded Delayed Response Working Memory
BOLD Functional magnetic resonance imaging (fMRI) changes in the blood-oxygen-level-dependent (BOLD) - signal, which changes in response to neural activity. Baseline fMRI measurements will be followed by rewarded delayed response Working Memory (WM) task measurements in which participants are required to remember the spatial location of a target stimulus (a dot) relative to a fixation cross. Participants are given feedback indicating success or failure. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in the Continuous Performance Test (CPT)
The CPT is a computerized test that assesses the participant's attention and vigilance. The participant was asked to attend to digits flashing on a computer screen and to click the mouse when the same string of digits flashed consecutively. The test consisted of 3 trials: the first contained 2-digit sequences, the second contained 3-digit sequences, and the third contained 4-digit sequences. Scoring was based the number of correct hits. The total score was an average of the 3 trials. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Brief Assessment of Cognition in Schizophrenia: Symbol-Coding
The Brief Assessment of Cognition in Schizophrenia (BACS): Symbol-Coding assesses the participant's speed of processing. The test is a timed paper-and-pencil test in which the participant uses a key to write digits that correspond to nonsense symbols. The key outcome variable for this task is the total number of correct, valid symbols in 90 seconds. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period and treatment group as fixed effects and participant nested within treatment sequence as a random effect.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Category Fluency Animal Naming Scores
The Category Fluency test assesses the participant's speed of processing. The test is administered orally, with the participant naming as many animals as he can in 1 minute. The key outcome variable for the test is the total number of correct, valid category words in 60 seconds. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Ventrolateral Prefrontal (VLPF) Cortex and Orbitofrontal (OFX) Cortex Activation During the Shift Trials
BOLD fMRI, a test that measures brain activity, was used during the Shifting Task at VLPF and OFX. Participants worked out which pair in a stimulus set consisting of a face and a building; transparent and overlapping, was the target. 1 pair appeared on the left of the screen, the other on the right. In each trial, participants indicated using a button box which side of the screen they thought the target was located on. Every second response, feedback was presented on the screen for 0.6 seconds, indicating whether or not the stimulus chosen was the target. If both of the last 2 choices were correct, the feedback was the word ''correct'' in green; otherwise, the feedback was the word ''incorrect'' in red. After 3 positive feedback events, a change of target occurred. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Ventral Striatum Activation During the Reward Trials
BOLD fMRI, a test that measures brain activity, was used during the Reward Task (Monetary Incentive Delay Test). Participants were instructed to respond as quickly as possible to a light-flash on the display screen. The flash was preceded by an arrow icon that informed participants about the consequences of their response to the flash stimulus. Four conditions were included in the paradigm, as follows: 1. Win condition (arrow up): win 2 pound sterling if the response was sufficiently fast. 2. Avoidance of loss condition (arrow down: lose 2 pound sterling if the response was too slow. 3. Verbal control (vertical double arrow): no gain or loss of money. 4. Passive control condition (horizontal double arrow): No response was required. Each of the above conditions was presented at least 10 times in a random order. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in P300 Amplitude at the Midline Parietal Electrode (Pz)
Brain electrical activity changes were quantified with electroencephalogram (EEG) battery tests. The P300 occurs after the presentation of a novel, behaviorally relevant target stimulus embedded among irrelevant stimuli. It reflects allocation of attention and activation of immediate memory. The amplitude of P300 indexes brain actions when the mental representation of the stimulus environment is updated, while its latency indexes stimulus classification speed unrelated to response selection processes. The participants are instructed to push a button when hearing the target stimulus, but not when hearing the standard. They are asked to press the button as fast as possible. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Mismatch Negativity (MMN) Amplitude at the Midline Frontal Electrode (Fz)
EEG, a test that measures brain electrical activity was performed during the MMN. The MMN is an auditory event related potential that is elicited by any discriminable change in auditory stimulation irrespective of the participant or participant's attention. The response to stimuli is being recorded by EEG electrodes while participants read a book. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Amplitude of the C1 Component of the Visual Evoked Potentials at the Midline Occipital Electrode (Oz)
EEG, a test that measures brain electrical activity was used. Participants had a baseline Visual Evoked Potentials (VEP) recording (2 minute checkerboard VEP) followed by a period of high frequency stimulation (2 minutes 9 Hz checkerboard stimulation). The VEP was repeated 2 minutes after the end of high frequency stimulation. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in High Beta/Low Gamma Power During Resting EEG
Participants are asked to open and close their eyes in 30 second alternating blocks to maintain an approximately constant level of arousal. The eyes closed EEG, a test that measures brain electrical activity, is dominated by alpha (8-14Hz) and the eyes open EEG dominated by beta (14-30Hz eyes open) with the two states analyzed separately to increase sensitivity to drug effects in these bands. Ratio is calculated as High Beta/Low Gamma Power. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Frontal Theta Power (EEG) During N-Back Working Memory Task
EEG, a test that measures brain electrical activity, was performed during the n-back task. In the n-back task participants are required to monitor a series of letters and report when the current letter matches the letter n integers back, where n=1 (1-back) or n=2 (2-back), the latter requiring a greater working memory resources. The task requires continuous updating of information stores. In the 0-back condition (which does not require manipulation of material in working memory), participants respond to the appearance of a pre-specified letter. The task consists of alternating 30-second (s) blocks of 0-back with 1-back, and 2-back conditions, with letters displayed every 2 s for 1 s within each block. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Positive subscale consists of 7 items which assesses the positive symptoms with subscale score ranging from 7 to 49, where higher score indicates greater severity. Negative subscale consists of 7 items which assesses the negative symptoms with subscale score ranging from 7 to 49, where higher score indicates greater severity. General psychopathology subscale consists of 16 items which assesses the general symptoms of schizophrenia with subscale score ranging from 16 to 96, where higher score indicates greater severity. A negative change from Baseline indicates improvement. ANOVA with treatment sequence, study period and treatment group as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
Time frame: Baseline and Day 8 of Treatment Periods 1, 2 and 3
Percentage of Participants Who Experience at Least 1 Treatment-Emergent Adverse Event
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From Day 1 until Day 63
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests
Percentage of participants with markedly abnormal safety laboratory tests (Hematology, Serum Chemistry and Urinalysis) collected throughout the study.
Time frame: From Day 1 until Day 63
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurement
Vital signs were oral body temperature, respiration rate, supine blood pressure (after 5 minutes resting), and pulse rate.
Time frame: From Day 1 until Day 63
Participants took part in the study at 1 investigative site in the United Kingdom from 13 March 2014 to 15 June 2015.
| Milestone | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg |
|---|---|---|---|
| Started | 6 | 7 | 7 |
| Completed | 6 | 7 | 5 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 2 |
| Milestone | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg |
|---|---|---|---|
| Started | 5 | 7 | 5 |
| Completed | 5 | 6 | 5 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Voluntary withdrawal | 0 | 1 | 0 |
| Milestone | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
The Spatial Span test assesses the participant's working memory. During this task, participants are presented with a board containing blue blocks randomly arranged. The rater first taps out a pattern of blocks, beginning with two blocks and increasing with participant proficiency, and the participant is tasked with tapping the same pattern. After discontinuation of this part of the subtest, the participant is then tasked with tapping out the reverse pattern after the rater's demonstration. These patterns also begin with two blocks and increase with participant proficiency. The total score for this subtest ranges from 0 (worst) to 32 (best). A positive change from Baseline indicates improvement. Analysis of Variance (ANOVA) with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
| score on a scale | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Spatial Span Test Score | -0.199 ± 0.5239 | 0.033 ± 0.5115 | -0.066 ± 0.5239 |
The HVLT assesses the participant's verbal learning. The test consists of a list of 12 words from three taxonomic categories which are presented orally, and the participant is asked to recall as many as possible after each of three learning trials. The key outcome variable for this task is the total correct responses in the three learning trials. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
| correct responses | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Hopkins Verbal Learning Test (HVLT) Score | -1.699 ± 1.0813 | 0.239 ± 1.0617 | 0.677 ± 1.0829 |
BOLD Functional magnetic resonance imaging (fMRI) changes in the blood-oxygen-level-dependent (BOLD) - signal, which changes in response to neural activity. Baseline fMRI measurements will be followed by rewarded delayed response Working Memory (WM) task measurements in which participants are required to remember the spatial location of a target stimulus (a dot) relative to a fixation cross. Participants are given feedback indicating success or failure. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect.
| unitless parameter estimates | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Dorsolateral Prefrontal Cortex Activation During the Rewarded Delayed Response Working Memory | 0.500 ± 0.1737 | 0.576 ± 0.1737 | 0.329 ± 0.1737 |
The CPT is a computerized test that assesses the participant's attention and vigilance. The participant was asked to attend to digits flashing on a computer screen and to click the mouse when the same string of digits flashed consecutively. The test consisted of 3 trials: the first contained 2-digit sequences, the second contained 3-digit sequences, and the third contained 4-digit sequences. Scoring was based the number of correct hits. The total score was an average of the 3 trials. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
| correct hits | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in the Continuous Performance Test (CPT) | 0.077 ± 0.1030 | 0.071 ± 0.1012 | 0.228 ± 0.1031 |
The Brief Assessment of Cognition in Schizophrenia (BACS): Symbol-Coding assesses the participant's speed of processing. The test is a timed paper-and-pencil test in which the participant uses a key to write digits that correspond to nonsense symbols. The key outcome variable for this task is the total number of correct, valid symbols in 90 seconds. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period and treatment group as fixed effects and participant nested within treatment sequence as a random effect.
| correct symbols | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Brief Assessment of Cognition in Schizophrenia: Symbol-Coding | 0.732 ± 1.8123 | 0.885 ± 1.7695 | 2.153 ± 1.8123 |
The Category Fluency test assesses the participant's speed of processing. The test is administered orally, with the participant naming as many animals as he can in 1 minute. The key outcome variable for the test is the total number of correct, valid category words in 60 seconds. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect.
| correct words | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Category Fluency Animal Naming Scores | -0.711 ± 0.8187 | 1.039 ± 0.8000 | -1.468 ± 0.8188 |
BOLD fMRI, a test that measures brain activity, was used during the Shifting Task at VLPF and OFX. Participants worked out which pair in a stimulus set consisting of a face and a building; transparent and overlapping, was the target. 1 pair appeared on the left of the screen, the other on the right. In each trial, participants indicated using a button box which side of the screen they thought the target was located on. Every second response, feedback was presented on the screen for 0.6 seconds, indicating whether or not the stimulus chosen was the target. If both of the last 2 choices were correct, the feedback was the word ''correct'' in green; otherwise, the feedback was the word ''incorrect'' in red. After 3 positive feedback events, a change of target occurred. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
| unitless parameter estimates | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Ventrolateral Prefrontal Cortex (VLPF) | 0.911 ± 0.3433 | 0.657 ± 0.3433 | 0.755 ± 0.3433 |
| Orbitofrontal Cortex (OFX) | 0.650 ± 0.3123 | 0.473 ± 0.3123 | 0.340 ± 0.3123 |
BOLD fMRI, a test that measures brain activity, was used during the Reward Task (Monetary Incentive Delay Test). Participants were instructed to respond as quickly as possible to a light-flash on the display screen. The flash was preceded by an arrow icon that informed participants about the consequences of their response to the flash stimulus. Four conditions were included in the paradigm, as follows: 1. Win condition (arrow up): win 2 pound sterling if the response was sufficiently fast. 2. Avoidance of loss condition (arrow down: lose 2 pound sterling if the response was too slow. 3. Verbal control (vertical double arrow): no gain or loss of money. 4. Passive control condition (horizontal double arrow): No response was required. Each of the above conditions was presented at least 10 times in a random order. ANOVA with treatment sequence, study period, and treatment as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
| unitless parameter estimates | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Ventral Striatum Activation During the Reward Trials | 0.321 ± 1.0316 | 0.544 ± 1.0316 | -0.255 ± 1.0316 |
Brain electrical activity changes were quantified with electroencephalogram (EEG) battery tests. The P300 occurs after the presentation of a novel, behaviorally relevant target stimulus embedded among irrelevant stimuli. It reflects allocation of attention and activation of immediate memory. The amplitude of P300 indexes brain actions when the mental representation of the stimulus environment is updated, while its latency indexes stimulus classification speed unrelated to response selection processes. The participants are instructed to push a button when hearing the target stimulus, but not when hearing the standard. They are asked to press the button as fast as possible. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
| microvolts (μV) | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in P300 Amplitude at the Midline Parietal Electrode (Pz) | -0.641 ± 0.9377 | -0.963 ± 0.9523 | 0.555 ± 0.9659 |
EEG, a test that measures brain electrical activity was performed during the MMN. The MMN is an auditory event related potential that is elicited by any discriminable change in auditory stimulation irrespective of the participant or participant's attention. The response to stimuli is being recorded by EEG electrodes while participants read a book. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
| μV | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Mismatch Negativity (MMN) Amplitude at the Midline Frontal Electrode (Fz) | -0.026 ± 0.2637 | 0.368 ± 0.2660 | -0.170 ± 0.2697 |
EEG, a test that measures brain electrical activity was used. Participants had a baseline Visual Evoked Potentials (VEP) recording (2 minute checkerboard VEP) followed by a period of high frequency stimulation (2 minutes 9 Hz checkerboard stimulation). The VEP was repeated 2 minutes after the end of high frequency stimulation. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
| μV | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Amplitude of the C1 Component of the Visual Evoked Potentials at the Midline Occipital Electrode (Oz) | -0.499 ± 0.6358 | -0.405 ± 0.6358 | -0.160 ± 0.6512 |
Participants are asked to open and close their eyes in 30 second alternating blocks to maintain an approximately constant level of arousal. The eyes closed EEG, a test that measures brain electrical activity, is dominated by alpha (8-14Hz) and the eyes open EEG dominated by beta (14-30Hz eyes open) with the two states analyzed separately to increase sensitivity to drug effects in these bands. Ratio is calculated as High Beta/Low Gamma Power. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect.
| ratio | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in High Beta/Low Gamma Power During Resting EEG | -0.127 ± 0.0689 | -0.078 ± 0.0673 | -0.040 ± 0.0709 |
EEG, a test that measures brain electrical activity, was performed during the n-back task. In the n-back task participants are required to monitor a series of letters and report when the current letter matches the letter n integers back, where n=1 (1-back) or n=2 (2-back), the latter requiring a greater working memory resources. The task requires continuous updating of information stores. In the 0-back condition (which does not require manipulation of material in working memory), participants respond to the appearance of a pre-specified letter. The task consists of alternating 30-second (s) blocks of 0-back with 1-back, and 2-back conditions, with letters displayed every 2 s for 1 s within each block. A positive change from Baseline indicates improvement. ANOVA with treatment sequence, study period, and treatment as fixed effects and subject nested within treatment sequence as a random effect was used for analysis.
| μV | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Change From Baseline in Frontal Theta Power (EEG) During N-Back Working Memory Task | -0.068 ± 0.0482 | -0.073 ± 0.0490 | 0.002 ± 0.0497 |
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Positive subscale consists of 7 items which assesses the positive symptoms with subscale score ranging from 7 to 49, where higher score indicates greater severity. Negative subscale consists of 7 items which assesses the negative symptoms with subscale score ranging from 7 to 49, where higher score indicates greater severity. General psychopathology subscale consists of 16 items which assesses the general symptoms of schizophrenia with subscale score ranging from 16 to 96, where higher score indicates greater severity. A negative change from Baseline indicates improvement. ANOVA with treatment sequence, study period and treatment group as fixed effects and participant nested within treatment sequence as a random effect was used for analysis.
| score on a scale | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Total Positive Score | -0.737 ± 0.9939 | -0.670 ± 0.9821 | -0.196 ± 1.0098 |
| Total Negative Score | 1.480 ± 1.0653 | 1.580 ± 1.0484 | 0.650 ± 1.0876 |
| Total General Psychopathology Score | 0.313 ± 1.5978 | -1.457 ± 1.5700 | -0.959 ± 1.6344 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Percentage of Participants Who Experience at Least 1 Treatment-Emergent Adverse Event | 56.3 | 41.2 | 47.4 |
Percentage of participants with markedly abnormal safety laboratory tests (Hematology, Serum Chemistry and Urinalysis) collected throughout the study.
| percentage of participants | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg |
|---|---|---|---|
| Hematology | 0 | 0 | 20.0 |
| Serum Chemistry | 20.0 | 14.3 | 0 |
| Urinalysis | 0 | 0 | 0 |
Vital signs were oral body temperature, respiration rate, supine blood pressure (after 5 minutes resting), and pulse rate.
| percentage of participants | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurement | 0 | 0 | 0 |
Collected over Up to 63 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/16 (6.3%) | 8/16 (50%) |
| Roflumilast 100 μg | — | 0/17 (0%) | 7/17 (41.2%) |
| Roflumilast 250 μg | — | 0/19 (0%) | 9/19 (47.4%) |
| Event | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| Suicide attemptPsychiatric disorders | 1/16 | 0/17 | 0/19 |
| Event | Placebo | Roflumilast 100 μg | Roflumilast 250 μg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/16 | 2/17 | 1/19 |
| HeadacheNervous system disorders | 1/16 | 1/17 | 2/19 |
| PalpitationsCardiac disorders | 1/16 | 0/17 | 0/19 |
| ToothacheGastrointestinal disorders | 1/16 | 1/17 | 1/19 |
| Catheter site bruiseGeneral disorders | 1/16 | 0/17 | 0/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/16 | 0/17 | 0/19 |
| Suicidal ideationPsychiatric disorders | 1/16 | 0/17 | 0/19 |
| RashSkin and subcutaneous tissue disorders | 1/16 | 0/17 | 0/19 |
| Rash macularSkin and subcutaneous tissue disorders | 1/16 | 0/17 | 0/19 |
| Scar painSkin and subcutaneous tissue disorders | 1/16 | 0/17 | 0/19 |
All randomized participants.
| Age, Continuous(years) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Mean | 34.8 ± 10.13 | 36.9 ± 10.38 | 48.1 ± 10.93 | 40.2 ± 11.63 |
| Sex: Female, Male(Participants) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 3 | 7 |
| Male | 4 | 5 | 4 | 13 |
| Race/Ethnicity, Customized(participants) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Asian | 0 | 1 | 1 | 2 |
| Black or African American | 5 | 5 | 4 | 14 |
| White | 1 | 1 | 2 | 4 |
| Region of Enrollment(participants) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| United Kingdom | 6 | 7 | 7 | 20 |
| Height(cm) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Mean | 169.8 ± 8.68 | 175.0 ± 7.64 | 169.1 ± 10.96 | 171.4 ± 9.14 |
| Weight(kg) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Mean | 79.38 ± 4.804 | 85.09 ± 17.406 | 81.41 ± 15.470 | 82.09 ± 13.532 |
| Body Mass Index (BMI)(kg/m^2) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Mean | 27.75 ± 3.871 | 27.56 ± 3.823 | 28.20 ± 3.158 | 27.84 ± 3.433 |
| Tobacco Classification(participants) | Placebo + Roflumilast 100 μg + Roflumilast 250 μg | Roflumilast 100 μg + Roflumilast 250 μg + Placebo | Roflumilast 250 μg + Placebo + Roflumilast 100 μg | Total |
|---|---|---|---|---|
| Never used tobacco | 1 | 1 | 3 | 5 |
| Current tobacco user | 2 | 4 | 3 | 9 |
| Ex-tobacco user | 3 | 2 | 1 | 6 |
1 further baseline measures are reported on the registry.
The record gives a start of Mar 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast